Tariffs Hit Home: Why U.S. Midsize Firms Are Suddenly Paying the Price

A year ago tariffs were a political slogan. Now they're a line item on balance sheets. New analysis from the JPMorganChase Institute finds that monthly tariff payments by midsized U.S. companies have roughly tripled since early 2025 — and the cost isn’t vanishing overseas. Instead, it’s landing squarely on American businesses, their workers, and ultimately consumers. (jpmorganchase.com)

Why this matters right now

• Midsize companies — those with roughly $10 million to $1 billion in revenue and under 500 employees — employ tens of millions of Americans and sit at the center of supply chains. A material cost shock for them ripples through local economies.
• The analysis comes amid a larger policy shift that raised average tariff rates dramatically in 2024–2025 and set off debates about who bears the burden: foreign suppliers, U.S. firms, or American consumers. The evidence is increasingly squarely on the U.S. side. (jpmorganchase.com)

Key points for readers pressed for time

• Tariff payments by midsize firms tripled on a monthly basis since early 2025. (jpmorganchase.com)
• The additional burden has been absorbed in ways that harm domestic outcomes: higher consumer prices, compressed corporate margins, or cuts in hiring. (the-journal.com)
• Some firms are shifting away from direct purchases from China, but it’s unclear whether that reflects true supply-chain reshoring or simple routing through third countries. (jpmorganchase.com)

The economic picture — beyond the headline

The JPMorganChase Institute used payments data to track how middle-market firms actually move money across borders. Their finding — a tripling of tariff outflows — is not just an accounting quirk. It reflects higher effective import taxes that many of these firms cannot easily avoid.

What that looks like on the ground:

• Retailers and wholesalers, with thin margins, face an especially acute squeeze; some will add markup, passing costs to shoppers. (apnews.com)
• Other firms will have to choose between accepting lower profits, cutting spending (including on hiring), or finding new suppliers. JPMorganChase’s data show some reduction in direct payments to China, but not enough to indicate a complete reorientation of sourcing. (jpmorganchase.com)

Why the distributional story matters: the policymakers who champion tariffs often frame them as taxes paid by foreign exporters. But multiple studies and payment-data analyses now point the opposite way — tariffs operate as a domestic cost that falls on U.S. businesses and consumers, with the burden concentrated on firms without the scale to absorb or dodge the charge. (apnews.com)

A few concrete numbers to anchor the debate

• The JPMorganChase Institute previously estimated that tariffs under certain policy scenarios could cost midsize firms roughly $82 billion; the tripling in monthly outflows is a complementary sign of how quickly those costs can materialize. (axios.com)
• Middle-market firms account for a large share of private-sector employment, so a change equal to a few percent of payroll can meaningfully affect hiring plans. (axios.com)

What firms are likely to do next

• Pass-through: Where competition allows, retailers and distributors will raise prices. Expect higher consumer prices in affected categories.
• Substitution: Some firms will seek suppliers in lower-tariff jurisdictions or route goods through third countries — a costly and imperfect fix that may increase lead times and complexity.
• Absorb: Many midsize firms lack pricing power and will instead accept smaller margins, delay investments, or cut labor costs.
• Hedge or pre-buy: Larger firms already stockpiled inventory during previous tariff surges; midsize firms can’t always do the same, which leaves them more exposed to sudden rate changes. (jpmorganchase.com)

Broader implications

• Inflation and politics: Tariffs operate like a tax that can nudge consumer prices upward. Even modest price effects matter politically when households feel pocketbook pain.
• Supply-chain strategy: The pattern of reduced direct payments to China suggests firms are adapting — but adaptation is slow and costly. Strategic decoupling from a major supplier nation isn’t instantaneous; it takes new contracts, quality checks, and often higher unit costs.
• Policy design: If the goal is to strengthen U.S. manufacturing, tariffs can help some producers while hurting downstream businesses and consumers. That trade-off underlines why empirical analysis of who actually pays the tariff is crucial to policy debates. (jpmorganchase.com)

My take

Tariffs are a blunt instrument. The new JPMorganChase Institute evidence makes a clear pragmatic point: when you raise the price of imports sharply and quickly, the economic pain shows up inside the country — not neatly absorbed by foreign suppliers. For policymakers who want to protect or grow U.S. industry, that doesn’t mean tariffs are useless, but it does mean they’re incomplete. If the aim is durable domestic job creation and competitiveness, tariffs should be paired with targeted industrial policy: investment in skills, R&D, logistics, and incentives that help midsize firms scale rather than simply shifting costs onto consumers or employees.

Sources

• JPMorganChase Institute — Tracking international payments: How are midsize firms reacting to tariffs?
  https://www.jpmorganchase.com/institute/all-topics/business-growth-and-entrepreneurship/tracking-international-payments-middle-market-firms-adapt-to-tariffs (jpmorganchase.com)

• Associated Press — Tariffs paid by midsize U.S. companies tripled last year, a JPMorganChase Institute study shows. Josh Boak, Feb 19–20, 2026.
  https://apnews.com/article/ (AP article mirrored widely; see AP coverage via news outlets). (the-journal.com)

• Axios — Tariffs add about $82 billion in costs for midsize U.S. companies. July 2025.
  https://www.axios.com/2025/07/02/trump-tariffs-costs-companies (axios.com)

• Associated Press (analysis) — Analysis shows Trump's tariffs would cost US employers $82.3 billion. July 2025.
  https://apnews.com/article/6fef729ff39ce24fcd46bbb60134b032 (apnews.com)

Markets breathe again after the Greenland tariff scare

The opening bell felt less like routine and more like damage control. Stocks went from a rout to a rally in a matter of news cycles after President Donald Trump announced he would not move forward with a set of Europe-targeted tariffs that had been expected to start on February 1. Investors who had been braced for a fresh global trade shock exhaled — and bought the dip. (washingtonpost.com)

Why this mattered so fast

• Tariff threats are different from ordinary headlines. They hit corporate margins, supply chains and the price of imports — and markets price those risks rapidly. When the president first threatened steep levies tied to his push over Greenland, U.S. indexes plunged and volatility spiked. (washingtonpost.com)
• The reversal removed an immediate policy overhang: with the tariff threat off the table for now, traders rotated back into cyclical and tech names that had sold off on worries about trade-driven earnings pressure. The result: a sharp, visible rebound in major indices. (investing.com)
• Wall Street’s sensitivity to abrupt trade-policy moves has been a recurring story — big policy swings can trigger outsized market moves, and sometimes the market’s reaction itself influences policy calibrations. (ft.com)

What happened, step by step

• Late weekend posts and comments from the White House signaled potential tariffs on a group of European countries in response to their resistance to U.S. pressure over Greenland. Markets immediately priced in the risk. The Dow plunged hundreds of points and the S&P and Nasdaq also gave back significant ground. (washingtonpost.com)
• As the diplomatic noise intensified — at Davos and in bilateral talks — investors watched for the administration’s next move. When the president announced he would not impose the planned tariffs beginning Feb. 1, major U.S. averages snapped higher within the trading day, recovering much of the prior losses. (investing.com)
• Traders described these moves as a classic “risk-on” bounce once the policy threat was removed; commentators also noted how rapidly political headlines can be priced in (or out) by markets. (ft.com)

Market implications for investors

• Short-term: volatility is likely to remain elevated around geopolitical or trade-related headlines. Fast reversals like this one can create opportunity — and risk — for traders who try to time headlines. (washingtonpost.com)
• Medium-term: corporate planning (sourcing, pricing, guidance) becomes harder when tariffs are used as leverage in foreign-policy disputes. Even when tariffs don’t land, the threat alone can affect decisions and valuations. (ft.com)
• Portfolio posture: diversification and a focus on fundamentals remain sensible for most long-term investors. For short-term participants, disciplined risk management is key when headline-driven moves dominate. (washingtonpost.com)

What the episode reveals about politics and markets

• Markets can act as a check — not in a formal way, but practically. Large, rapid sell-offs increase political costs and pressure decision-makers to recalibrate. That dynamic appears to have played out here, with market reactions amplifying the consequences of the tariff threat. (ft.com)
• At the same time, frequent policy flip-flops create a new baseline for volatility. Investors may grow used to headline swings, but “getting used to it” is not the same as being immune. Tail risks still exist and can surprise complacent portfolios. (washingtonpost.com)

Key takeaways

• Major U.S. indices rebounded after the administration dropped planned Europe tariffs set for Feb. 1, turning a sell-off into a rally. (investing.com)
• Tariff talk alone can move markets: the initial threat caused a sharp sell-off and a spike in volatility. (washingtonpost.com)
• Even when a policy threat is withdrawn, the episode raises longer-term questions about unpredictability, supply-chain risk and how investors price political risk. (ft.com)

My take

This episode is a microcosm of modern market-politics interactions: headlines travel fast, markets react faster, and the political calculus sometimes shifts under the weight of market consequences. For investors, the practical lesson is simple and recurring — respect the headlines, but anchor decisions in company fundamentals and risk management. Short-term traders can profit from volatility, but only with a clear plan and limits.

Sources

• Stocks slide after Trump threatens new tariffs over Greenland. The Washington Post. Updated January 20, 2026.
  https://www.washingtonpost.com/business/2026/01/20/stocks-trump-tariffs-greenland/ (washingtonpost.com)

• S&P 500 jumps as tariff angst eases on Greenland framework deal. Investing.com. January 20–21, 2026.
  https://www.investing.com/news/stock-market-news/us-stock-futures-inch-higher-after-wall-st-tumbles-on-greenland-tariff-fears-4456659 (investing.com)

• Donald Trump's tariff 'shock regime' tests Wall Street's mettle. Financial Times. (Analysis on market influence of tariff threats.)
  https://www.ft.com/content/cb1a8211-ac60-4cb2-b68f-955f3d0f98f5 (ft.com)

• Dow drops after Trump threatens European allies with tariffs over Greenland. CBS News. January 20, 2026.
  https://www.cbsnews.com/news/stock-market-down-january-20-trump-greenland/ (cbsnews.com)

Johnson & Johnson’s deal with the U.S. government: what it means for drug prices, tariffs, and American manufacturing

A deal that’s equal parts policy, public relations, and industrial strategy landed on January 8, 2026: Johnson & Johnson announced a voluntary agreement with the U.S. government to lower medicine costs for millions of Americans while securing an exemption from potential tariffs — and pledging new domestic manufacturing investments. It’s one of several recent pacts between major drugmakers and the administration, and it touches on three hot-button issues at once: affordability, trade policy, and reshoring of pharmaceutical production. (jnj.com)

Why this caught headlines

• The company says millions of Americans will be able to buy J&J medicines at “significantly discounted rates” through a direct purchasing pathway described in the announcement. (jnj.com)
• In exchange, J&J’s pharmaceutical products receive an exemption from tariffs under the administration’s Section 232 trade scrutiny — a form of regulatory certainty that can materially affect margins and strategy. (jnj.com)
• The firm also confirmed further U.S. investment: two additional manufacturing facilities (cell therapy in Pennsylvania; drug product manufacturing in North Carolina) as part of its previously announced $55 billion U.S. investment plan. (jnj.com)

Those three elements—price concessions, tariff relief, and capital commitments—create a compact meant to satisfy both political and business imperatives. But beneath the headlines are subtler trade-offs and questions about scope, transparency, and longer-term impact.

Quick takeaways for readers scanning this

• J&J will offer discounted medicines to Americans via a direct-purchase program; exact drugs and discount levels were not disclosed in the press release. (jnj.com)
• The agreement provides a tariff exemption tied to continued U.S. investment in manufacturing, echoing similar arrangements other pharma firms have struck. (pharmamanufacturing.com)
• J&J is moving forward on domestic capacity: new sites in North Carolina and Pennsylvania add to its ongoing $55 billion commitment to U.S. manufacturing and R&D. (jnj.com)

Context: where this fits into the bigger picture

Drug pricing has been a political lightning rod for years. Policymakers are pushing for lower out-of-pocket costs and for the U.S. to stop shouldering a disproportionate share of global drug prices. At the same time, the administration’s tariff and trade posture has created uncertainty for multinational pharma companies that import materials or finished products. The recent flurry of voluntary agreements — in which companies promise price concessions or program participation in exchange for regulatory certainty and encouragement to invest domestically — is an attempt to square those circles. (reuters.com)

From industry perspective, the carrot of tariff relief plus a runway for U.S.-based manufacturing can be persuasive. From public interest and policy angles, voluntary deals leave open questions about which medicines are affected, how savings are passed to patients and taxpayers, and what accountability measures exist. Several recent announcements from peers show similar frameworks; secrecy around specific terms is a recurring criticism. (pharmamanufacturing.com)

What to watch next

• Specific drug list and discount details: The J&J release did not name which medicines would be included or the depth of discounts. Those details determine whether the move benefits a broad population or a narrower set of patients. (jnj.com)
• Timeline and duration of the tariff exemption: Other agreements have included multi-year grace periods; the length and conditionality matter for corporate planning and taxpayer exposure. (pharmamanufacturing.com)
• Job creation and plant timelines: J&J projects thousands of construction and manufacturing jobs from its investments; tracking actual hiring and capital deployment will show how much reshoring is real vs. aspirational. (jnj.com)
• Regulatory and legislative interplay: Ongoing Medicare negotiation rules, state-level reforms, and future trade actions could change incentives and the real-world effect of voluntary pacts. (apnews.com)

The investor dilemma

For investors, these deals can be double-edged:

• Positive: tariff certainty and clearer regulatory backdrop can reduce downside risk and encourage capital spending that strengthens future growth. (jnj.com)
• Negative: pricing concessions and participation in discount platforms could compress margins, especially if applied to high-revenue drugs or expand over time. Transparency around which products are included will be crucial to modeling impacts. (reuters.com)

My take

This agreement is smart politics and pragmatic business strategy wrapped together. It’s pragmatic because it buys the company regulatory breathing room and a path to expand domestic capacity—both defensible corporate goals. It’s political because offering discounted access addresses immediate public anger over drug prices, even if the long-term structural drivers of U.S. drug costs are not fully resolved by voluntary deals alone. What matters now is follow-through: clear lists of included medicines, measurable patient savings, and verifiable timelines for the manufacturing investments. Without those, good press risks becoming little more than a headline. (jnj.com)

Final thoughts

Deals like this will likely keep appearing as administrations try to lower healthcare costs without upending the pharmaceutical innovation engine. For patients, any program that lowers out-of-pocket costs is welcome — provided the discounts are meaningful and accessible. For policymakers and watchdogs, the job is to demand the transparency and metrics that turn press releases into policy outcomes: who benefits, by how much, and for how long.

Sources

• Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments — Johnson & Johnson. https://www.jnj.com/media-center/press-releases/johnson-johnson-reaches-agreement-with-u-s-government-to-improve-access-to-medicines-and-lower-costs-for-millions-of-americans-delivers-on-u-s-manufacturing-and-innovation-investments
• J&J strikes deal with US government to cut drug prices, gain tariff exemptions — Reuters (Jan 9, 2026). https://www.reuters.com/business/healthcare-pharmaceuticals/johnson-johnson-reaches-deal-with-us-government-lower-drug-prices-2026-01-09/
• J&J secures tariff exemption in drug pricing deal with Trump administration — Pharma Manufacturing. https://www.pharmamanufacturing.com/facilities/article/55342361/jj-secures-tariff-exemption-in-drug-pricing-deal-with-trump-administration
• Trump administration says lower prices for 15 Medicare drugs will save taxpayers billions — Associated Press. https://apnews.com/article/53602fe0b5b7800030c475c3a5f34c3c

When the jobless rate climbs, a political narrative starts to wobble

There’s a particular hum in Washington when a jobs report walks in slightly off-script: markets twitch, talking heads adjust their tone, and political teams scramble for new soundbites. The headline from mid-December was blunt — the unemployment rate rose, even as the economy added a modest number of jobs — and that small shift has outsized implications for an administration that has made “economic comeback” central to its pitch to voters.

Below I unpack why a rising jobless rate matters politically, what’s driving the softening labor market, and why this is more than just a numbers game.

What happened — the quick version

• In the latest Labor Department snapshots, the unemployment rate ticked up to the mid-4 percent range (reports around the December jobs release put it at roughly 4.6% for November), while payroll gains were modest. (wsj.com)
• Revisions and one-off cuts — notably large reductions in federal payrolls earlier in the year — have removed a cushion that previously helped headline job growth. (washingtonpost.com)
• Other indicators — weaker hiring in manufacturing and finance, slower wage growth, and falling private job openings — point to a labor market that’s cooling rather than collapsing. (businessinsider.com)

Why this stings Trump’s economic messaging

• The core of the Trump message has been: my policies deliver jobs and rising incomes. Voters notice the jobless rate more than they notice GDP nuance. A rising unemployment rate is a visceral, easy-to-grasp signal that “the economy isn’t working for people.” (politico.com)
• Politics is about attribution. When unemployment climbs, the incumbent is the default target; opponents and the press will link labor weakness directly to administration choices — tariffs, federal workforce cuts, and policy uncertainty — even if causes are mixed. (americanprogress.org)
• Messaging mismatch: The White House can point to private-sector gains and labor-force entrants as explanations, but those arguments are weaker if people feel longer job searches, slower pay growth, or layoffs in local industries. Numbers that look small in D.C. spreadsheets translate to real pain on Main Street. (whitehouse.gov)

What’s behind the shift in the labor market

• Policy headwinds: Tariff uncertainty and trade policy shifts have raised costs for some manufacturers and importers, prompting hiring freezes or cuts in certain sectors. (businessinsider.com)
• Federal payroll reductions: Large federal workforce cuts earlier in the year removed a steady source of employment and ripple effects into the private firms that depend on government contracts. (washingtonpost.com)
• Monetary legacy and demand cooling: The Federal Reserve’s earlier cycle of high interest rates and their lagged effects are still tamping down investment and hiring in interest-sensitive sectors. That, plus slower wage growth, reduces hiring incentives. (ft.com)
• Structural changes: Automation, AI adoption, and shifting sectoral demand mean some occupations face lasting disruption, complicating the short-term picture. (businessinsider.com)

Voter dynamics and the election arithmetic

• Timing matters. If the labor market continues to weaken heading into an election year, skepticism about economic stewardship becomes a tangible drag. Voters who once prioritized pocketbook improvements are quicker to notice higher joblessness and slower hiring. (politico.com)
• The administration can still shape the narrative (point to private-sector job creation, rising participation, or short-term payroll gains), but repetition works only so long if local experiences tell a different story. Campaigns that rely on economic credibility are particularly vulnerable to a steady, measurable rise in unemployment. (whitehouse.gov)

What to watch next

• Monthly Labor Department jobs reports and revisions: small headline changes can have big political effects once they stack into a trend. (wsj.com)
• Federal employment and contract dynamics: more cuts or restorations will directly affect regions and industries that provide campaign reach. (washingtonpost.com)
• Wage trends and jobless-duration metrics: growing spell lengths or falling real wages are the signals that sway everyday voters more than the unemployment number alone. (wsj.com)
• Fed policy shifts: if the Fed moves aggressively on rates, it will change the trajectory of hiring and investment, with clear political consequences. (ft.com)

Quick takeaways

• A rising unemployment rate punches above its weight politically — it’s shorthand for “economy not delivering.” (wsj.com)
• Policy choices (tariffs, federal cuts) and lingering monetary effects are combining with structural labor shifts to cool hiring. (americanprogress.org)
• The administration can frame the data in ways that defend its record, but sustained labor-market deterioration would make persuasive messaging much harder. (politico.com)

My take

Numbers move markets, but narratives move voters. A single uptick in unemployment doesn’t end a presidency. But in politics, perception is cumulative: a steady string of softer labor reports can erode the economic credibility that incumbents depend on. For an administration that’s built a central narrative around jobs and prosperity, the safe play is twofold — stabilize the labor market with clear, targeted policy and lay out an honest, localized story that connects policy moves to tangible results for working people. Spin only stretches so far when someone in your town has been looking for work longer than they used to.

Sources

• U.S. Unemployment Rose in November Despite Job Gains — Wall Street Journal. https://www.wsj.com/economy/jobs/jobs-report-october-november-2025-unemployment-economy-7f6eea90. (wsj.com)

• Employers added 64,000 jobs in November; unemployment rate at 4.6% — The Washington Post / AP coverage. https://www.washingtonpost.com/politics/2025/12/16/jobs-economy-trump-unemployment-federal-reserve/6874b5fa-da3c-11f0-b484-4459fa8e79e5_story.html. (washingtonpost.com)

• Job Growth Slows as Trump Policies Raise Costs and Cut Jobs — Center for American Progress. https://www.americanprogress.org/press/release-job-growth-slows-as-trump-policies-raise-costs-and-cut-jobs/. (americanprogress.org)

• The job market isn't as good as we thought. There might be an upside for Trump. — Politico. https://www.politico.com/news/2025/08/01/jobs-report-federal-reserve-interest-rates-00488229. (politico.com)

• The politics of the Fed and the labor market — Financial Times. https://www.ft.com/content/b0495ea7-a6ee-470d-b9ef-e49c2006d058. (ft.com)

(Note: URLs above are non-paywalled where available; some outlets may require free registration.)